Page 631«..1020..630631632633..640650..»

Holy wars against vaccines and science People’s World – People’s World

Posted: October 16, 2021 at 2:30 am

The Museum of the Bible in Washington posts "COVID Commandments" to keep visitors safe. Some Evangelical figures take an opposite stance, spreading disinformation and skepticism about coronavirus vaccines and safety measures. | Tom Williams/CQ Roll Call via AP

Last summer, some of my family visited folks in Pennsylvania. All of us leaving the Bronx were fully vaccinated. Mask-wearing compliance on Amtrak was basically 100%the conductors told passengers who werent wearing masks to put them on. Unlike too many passengers I see daily on city buses and the subway system, those passengers complied without complaint.

While walking to the car after reaching our destination, I discovered the mother of our host family was not vaccinated. The father laughed at my mask, which I forgot to remove, but he didnt know Amtrak required them. His state had recently lifted mask mandates for people inside restaurants and stores.

The family is evangelical Christian, so I wasnt entirely surprised at the revelations. To be a non-controversial guest, I chose to not discuss the issue. But one night while watching cable news coverage on the growing Delta variant, I commented aloud that we werent through the crisis. The headline was that even vaccinated people were getting infected.

A better headline would have been that the unvaccinated were much more likely to catch the virus. For example, in New York City, 96% of coronavirus patients are unvaccinated. Those fully vaccinated account for less than one percent of the cases.

Anyway, the news report prompted one of the children to ask me, why bother getting vaccinated? Besides, he continued, the Centers for Disease Control was inflating the number of infected people.

My heart sank hearing this misinformation. I told him I had watched, listened to or read the news every day, and I never came across that claim. I wondered who told him that. Was the family minister giving the OK to decline vaccines? Again, questions best avoided in order to keep the peace.

I am sure my suspicion was correct. My outgoing city council member, and before that, my state senator, Rev. Rubn Daz, Sr., recently confirmed it. In his Sept. 21 edition of his What You Should Know newsletter, he explained why so many people of faith, especially Christian Evangelicals, are opting out of getting Covid Vaccines.

Daz cites 1 Corinthians 6: 1920. This passage tells Christians that their bodies are temples of the Holy Spirit who is inside the bodies of believers. Since Christians are not [their] own, they must honor God with [their] bodies. The selection does not and could not possibly discuss vaccines. Perhaps inoculations against smallpox reach back a thousand years, in China, northern Africa, and Turkey. The First Letter of Paul to the Corinthians was written nearly a thousand years before those first inoculations. And vaccines have been around for only some 200 years.

Beyond the theological basis, religious objections against vaccinations usually protest that stem cells are often used in their development. Recently, this has been confused with incorrect claims that COVID-19 vaccines contain stem cells from aborted fetuses. Much breakthrough scientific research would not be so without stem cells. To be consistent, Tylenol, Pepto Bismol, Ibuprofen, Motrin, and other products would also have to be refused.

In our secular society, should all religious objections be considered authentic? Federal guidelines and previous court decisions guide employers to make judgments. Employers can ask if the workers behavior shows consistency with the religious belief. Is a religious reason being used as a convenience for secular, non-religious benefits? Does the timing of the religious objection make it suspicious? Does the employer have good reason to doubt that the religious objection is not sincere?

In 2016, Vermont removed nonreligious beliefs as a way out of vaccine requirements for public schools kindergarten admission. Immediately, the number of religious exemption cases spiked. In other words, people grabbed onto religious objections when other objections could not be used.

For generations, vaccines have been required for entrance into our public schools, to prevent outbreaks of smallpox, polio, diphtheria, rubella, measles, chickenpox. And for decades, objections did not overlap with politics. Now, in a much more polarized America, Republicans are far more likely to skip the coronavirus vaccine.

Daz likewise argues that the fear of side effects is a valid reason to refuse vaccinations. Especially because, he implies, no one will be liable for pressuring people into getting the shot(s), should a horrible side effect unfold.

He and the unvaccinated are failing probability class. Yes, it is possible that serious side effects can cause long-term problems, but that is extremely unlikely. More likely are mild and short-lived side effects, but COVID-19 damage is often long lasting and even fatal.

Rev. Daz claims so many people of faith are refusing vaccination. But this is simply false. Evangelical Christians are the outlier; most religious leadership disagrees.

The Pope and the U.S. Conference of Catholic Bishops are telling Catholics to get vaccinated. Pope Francis is vaccinated and said it would be suicide to not do so. He calls getting vaccinated an act of love.

Similarly told are followers of the Greek Orthodox Archdiocese of America, as are Eastern Orthodox worshippers, represented by the Holy Eparchial Synod of the nationwide archdiocese.

The same tidings are preached by the Evangelical Lutheran Church in America and the Rev. Robert Jeffress of First Baptist Dallas, a Southern Baptist megachurch. Add to the list the Church of Jesus Christ of Latter-day Saints.

In some cases, these religious groups are requiring their students or their missionaries to be vaccinated. In other cases, vaccines are urged though not via official policy statements. Examples here are the United Methodist Church and the Orthodox Union, an umbrella organization for Orthodox Judaism. The Islamic scholars of the Fiqh Council of North America advise Muslim believers to get their shots and argue against baseless rumors and myths about vaccines.

Jehovahs Witnesses are also urged to become protected. Despite their long history of opposition to vaccinations, Christian Scientists are open to the vaccines that fight COVID-19.

My soon-to-be-retired city council member also argues that some people already have acquired Natural Herd Immunity. Another F grade, this time for science class.

Herd immunity is synonymous with community immunity. It doesnt happen to individuals unless it occurs to the collective. How does it come about? Either massive numbers are vaccinated or so many get the disease, the spread from one person to another is no longer likely. The disease or virus still spreads, but only on an individual level. It doesnt tear through entire cities, states, towns, etc.

To repeat the nonsense from Paul Kengor of The American Spectator is reckless. Kengor argues that herd immunity via community infection is superior to immunity via vaccines. The truth is that the first path has major problems. One is possible reinfection, much more likely with the unvaccinated. The other pitfall is that it would take probably 70% of the U.S. population to get COVID-19 and recover for natural immunity to occur.

Should leaders, whether from the pulpit or not, believe conservative political sources or the Mayo clinic for guidance about COVID-19? Daz chooses the first source, the one that advertises impeached President Trump hawking Minuteman Bill Of Rights Gold Half Dollars.

The same American Spectator article cites a study claiming that people who recovered from COVID do not get additional benefits from vaccination. Scientists wholeheartedly disagree. There is evidence that those who have recovered from the coronavirus but are not vaccinated are more than two times as likely to get re-infected compared to people who are fully vaccinated.

Rev. Daz is vaccinated, but he does not pressure his church members or visitors to follow suit. He blesses emotional and physical objections but gives more weight to spiritual reasons. Are we to believe that the unvaccinated in his congregation know more about the Good Book than he? Why is the vaccine necessary for him but not for the flock?

The best of our elected officials have lost patience with voluntary vaccination schemes. New York State now requires health care workers to get their shots. If they dont, they will lose their jobs. A week before the requirement, 82% of the states nursing home workers and about 84% of its hospital workers had received one or more doses. When the mandate was in place, the figures jumped to 92%. The two groups overall are much more protected than the rest of society, but I wonder if the 8% holdouts are listening to Rev. Daz and similar voices.

Does freedom of religion potentially harm public safety? Some ancient religions used human sacrifice to please the gods. Their societies were not scientific and were bewildered by volcanic eruptions, hurricanes, epilepsy, and the like. Today, we would all agree that killing humans is not the answer to natural disasters, germs, and viruses. We must ask, does blessing opposition to vaccines potentially harm too many people? Ask the staffs of hospitals that are overrun with COVID-19 cases and that must turn away other medical problems.

On this point, my city council member-to-be, Amanda Faras, enters the debate. Throughout the pandemic, Faras has distributed masks, food, and hand sanitizerand correct information about vaccines. An Oct. 5 statement argues that unvaccinated COVID-19 cases are harmful to the community in their own right. And by unnecessarily filling up hospital beds, they are crowding out other patients, such as women with breast cancer, the second leading cause of cancer among women.

Taking a polar opposite approach from the man who retired rather than face her in an election, Faras tells the people of her district that we must not only take care of ourselves but also take care of our neighbors. How? By getting vaccinated. A link in the release lands readers to vaccination locations throughout large areas of the Bronx.

Rev. Daz should be more careful. I cant object to his sincere religious objections. But his newsletter raises far more than matters of faithit spreads numerous scientific falsehoods. And it circulates beyond his email list via his Twitter feed as well as its reproduction in many local Bronx printed and online publications. These include The Bronx Chronicle, Newsbreak, La Voz Internacional, 100 Percent Bronx, various Facebook pages. Online coverage means the message spreads beyond the borough.

We need leadership if we are to make it through the coronavirus era. Rev. Daz and similar voices are failing their own constituents and followers. And like the virus itself, the damage cannot be contained.

As with all op-eds published by Peoples World, this article reflects the opinions of its author.

Link:
Holy wars against vaccines and science People's World - People's World

Posted in New York Stem Cells | Comments Off on Holy wars against vaccines and science People’s World – People’s World

Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial – OncLive

Posted: October 16, 2021 at 2:30 am

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very highrisk myelodysplastic syndrome.

Standard-of-care options for patients with intermediate-, high-, and very highrisk myelodysplastic syndrome (MDS) have plateaued in their efficacy, leading investigators to seek alternative novel therapies. The initiation of the phase 3 ENHANCE trial (NCT04313881) looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody.1

There are only 2 treatments available [for these patients], said Eytan M. Stein, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, in an interview with OncologyLive. These options are essentially 2 sides of the same coin. They are both hypomethylating agents; one is azacitidine [Vidaza] and the other is decitabine [Dacogen].

Azacitidine was approved for all types of MDS in May 2004 based on results of the phase 3 Cancer and Leukemia Group B 9221 study in which the agent elicited a 16.2% response (n = 16/99) compared with no response with placebo (n = 0/92); response rates in similar single-arm studies ranged from 11.8% to 18.8%.2 Similar results were observed to support the FDA approval of decitabine in 2006; the response rate was 21% among 56 evaluable patients treated with the agent vs 0% in the supportive care arm (n = 89).3

We know from clinical studies that were done about a decade ago that theyre better than doing nothing, which is what we had before these treatments, Stein said. But theyre certainly not good enough. The remission rate is in the range of 30% to 40%, [and] survival is somewhat limited. For this patient population, another key factor is that even in the patients who do respond to these drugs, they typically stop working after a year or two. The duration of response [DOR] is not particularly long. Theres a real need for new agents for MDS.

ENHANCE will evaluate the efficacy of magrolimab in combination with azacitidine, compared with azacitidine plus placebo in previously untreated participants with intermediate-, high-, or very highrisk MDS.1 Preclinical models have shown synergistic effects of combining hypomethylating agents with immune checkpoint inhibitors, and investigators have hypothesized that the combination may overcome resistance mechanisms that arise with hypomethylating agents alone.4

Magrolimab blocks CD47, a key do not eat me signal that is often overexpressed on tumor cells. The binding of magrolimab to CD47 induces potent macrophage- mediated phagocytosis of tumor cells. Azacitidine synergizes with magrolimab by increasing expression of prophagocytic eat me signals.5-7

There was a lot of good preclinical science that was done primarily in laboratory work by Ravi Majeti MD, PhD, at Stanford [University in California], Stein noted. This [preclinical work] showed that by giving an anti-CD47 antibody, you can get this immunologic approach where you can eradicate the MDS cells, the bad cells, that are causing the problem. The [inhibition of the] do not eat me signal allows macrophages to basically recognize the malignant MDS cells, which then allows them to be eradicated through phagocytosis.

Investigators examined the combination of magrolimab and azacitidine in patients with hematological malignancies in a phase 1b trial (NCT03248479). A total of 39 patients with MDS have been treated with the combination. The median age of this cohort was 70 years (range, 47-80) and 13% of patients harbored a TP53 mutation.7

Magrolimab was given via a priming/intrapatient dose-escalation regimen of 1 to 30 mg/kg once a week for the first 2 cycles, then once every 2 weeks in cycles 3 and beyond. Azacitidine was administered at a dose of 75 mg/m2 on days 1 to 7.

Among 33 patients evaluable for efficacy, the objective response rate (ORR) was 91% with 42% of responders achieving complete remission (CR). Several responses deepened over time; patients with at least a 6-month follow-up achieved a CR rate of 56%. The median overall survival (OS) has not been reached (95% CI, 1.4-18.3), and the 6-month estimated OS rate is 100%.7

Cytogenetic CRs were observed in 35% of efficacy-evaluable patients, with 91% of responding patients having a continuing response at 6 months. The median time to initial response was 1.9 months. Minimal residual disease negativity by multi- parameter flow cytometry was reported in 22% of patients with CR, CR with incomplete hematologic recovery, or marrow CR.7

Regarding safety, the most common adverse effects (AEs) of any grade were anemia (44%), fatigue (18%), infusion reaction (18%), and neutropenia (8%). No patients in the MDS cohort discontinued treatment because of an AE, and no treatment-related febrile neutropenia was seen by investigators.7

The median decrease in hemoglobin with the first dose of magrolimab plus azacitidine was 0.4 g/dL. Investigators noted that the combination had a similar safety profile compared with azacitidine monotherapy.7

Magrolimab actually possesses a fairly good toxicity profile; it doesnt have many significant AEs, Stein said. The most significant AE is that patients can experience an on-target anemia, which can be pretty dramatic at the onset. Also, in some patients, you can see the hemoglobin dropped by 2 to 3 grams.

The phase 3 trial will enroll approximately 520 previously untreated adult patients with intermediate-, high-, very highrisk MDS by Revised International Prognostic Scoring System in the United States, Europe, Asia, and Australia [Figure8]. To be eligible for the study, patients must have adequate performance status and hematological, liver, and kidney function. Patients will be evenly randomized to receive either magrolimab plus azacitidine or placebo plus azacitidine.1,8

Ineligible patients include those with active hepatitis B, C, and/or HIV after testing at screening or in their medical history. Patients previously treated with anti-CD47 or signal-regulatory protein -targeting agents are not eligible for the trial. Patients with clinical suspicion of active central nervous system involvement or those who are pregnant or actively breastfeeding also will be excluded.8

Patients in the trial cannot have undergone any prior antileukemic therapy for treatment of intermediate-, high-, or very highrisk MDS. Patients with contraindications to azacitidine will be excluded, as well as those who have immediate eligibility for allogenic stem cell transplant with an available donor, as determined by the investigators.8

Patients in the experimental arm will receive a 1 mg/kg dose of magrolimab intravenously on days 1 and 4 of cycle 1, followed by 15 mg/kg on day 8, and 30 mg/kg on days 11, 15, and 22. In cycle 2, patients will be given 30 mg/kg of magrolimab on days 1, 8, 15, and 22. In cycle 3 and beyond, 30 mg/kg of magrolimab will be administered every 2 weeks on days 1 and 15.1,8

Stein said that a change in the trial designtreating patients frequently with smaller doses at the starthelped to curb some of the common AEs. As a result of [this dosing schedule], we believe that is going to help prevent this anemia that you may see, he said.

In the control arm, placebo to match magrolimab will be administered intravenously. In both arms, azacitidine will be given at 75 mg/m2 on days 1 to 7, or days 1 to 5 and 8 to 9 of each cycle, either subcutaneously or intravenously according to region-specific drug labeling.8

The primary end points of the trial are CR rate and overall survival. Key secondary end points include duration of CR, ORR, DOR, and progression-free survival. The trial is estimated to be completed by February 2025.8

I believe magrolimab with azacitidine will become the standard of care, Stein concluded. If [the data] pan out in this phase 3 trial, it would be the first real immunotherapy/checkpoint inhibitor treatment for a myeloid malignancy. People talk about PD-L1 and PD-1 inhibitors in solid tumors [but] we havent had something that really works like that in patients with MDS or acute myeloid leukemia. If this [regimen] does work in the phase 3 setting, its a proof of concept that there is an immunologic therapy that you can give that can make outcomes in patients better in this class of diseases.

Visit link:
Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial - OncLive

Posted in New York Stem Cells | Comments Off on Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial – OncLive

Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue – EurekAlert

Posted: October 16, 2021 at 2:29 am

BUFFALO, N.Y. The global race to develop new stem cell-based COVID-19 treatments during the pandemic was filled with violations of government regulations, inflated medical claims and distorted public communication, say the authors of a new perspective published Oct. 14 in the journal Stem Cell Reports.

While stem cell therapy using stem cells to promote regeneration, repair or healing may be used to treat a limited number of diseases and conditions, there are currently no clinically tested or government-approved cell therapies available for the treatment or prevention of COVID-19 or its long-term effects.

However, this has not stopped the emergence of clinics offering unproven and unsafe stem cell therapies that promise to prevent COVID-19 by strengthening the immune system or improving overall health, says lead author Laertis Ikonomou, PhD, associate professor of oral biology in the University at Buffalo School of Dental Medicine.

The article explores the negative effects that misinformation about cell therapies has on public health, as well as the roles that researchers, science communicators and regulatory agencies should play in curbing the spread of inaccurate information and in promoting responsible, accurate communication of research findings.

Efforts to rapidly develop therapeutic interventions should never occur at the expense of the ethical and scientific standards that are at the heart of responsible clinical research and innovation, says Ikonomou.

Scientists, regulators and policymakers must guard against the proliferation of poorly designed, underpowered and duplicative studies that are launched with undue haste because of the pandemic, but are unlikely to provide convincing, clinically meaningful safety and efficacy data, says co-author Leigh Turner, PhD, professor of health, society and behavior at the University of California, Irvine.

Other investigators include Megan Munsie, PhD, professor of ethics, education and policy in stem cell science at the University of Melbourne; and Aaron Levine, PhD, associate professor of public policy at Georgia Institute of Technology.

Unsafe products linked to unproven claims

Many of the studies on possible stem cell-based COVID-19 treatments are at an early stage of investigation and further evaluation on larger sample sizes is required, says Munsie. However, the findings from preliminary studies are frequently exaggerated through press releases, social media and uncritical news media reports.

Given the urgency of the ongoing pandemic, even the smallest morsel of COVID-19 science is often deemed newsworthy and rapidly enters a social media landscape where regardless of its accuracy it can be widely shared with a global audience, says Levine.

Clinics selling supposed stem cell treatments on a direct-to-consumer basis sometimes use these findings and news reports to exploit the fears of vulnerable patients by unethically advertising the unproven benefits of stem cell treatments to boost the immune system, regenerate lung tissue and prevent transmission of COVID-19, says Turner.

There are reports of patients suffering physical harm including blindness and death from unproven stem cell therapies. Patients suffer financially as well, says Ikonomou, as the products range in price from a few thousand to tens of thousands of dollars, and people are often encouraged to receive the expensive treatments every few months.

Patients led to believe they are protected against COVID-19 may decide against vaccination, stop wearing masks, cease engaging in physical distancing, or otherwise avoid behaviors intended to promote personal safety and public health, says Turner. They may also become less likely to take part in carefully-developed clinical trials conducted by companies that follow ethical standards.

The premature commercialization of cell-based therapeutics will inevitably harm the field of regenerative medicine, increase risks to patients and erode the publics trust, says Ikonomou.

Taking stronger action

The United States Food and Drug Administration and Federal Trade Commission have issued warnings to numerous offending clinics, yet many companies continue to make false claims.

The authors recommend that regulatory agencies consider implementing stronger measures to deter the sale of unlicensed products, such as issuing fines or criminal charges, revoking medical licenses or forcing clinics to return money to patients.

They also suggest that scientific and professional societies lobby regulatory agencies to increase enforcement of laws and regulations. Science communicators and journalists can combat misinformation by not engaging in hyperbolic coverage of research results and conveying study limitations, say the authors.

###

Stem Cell Reports

Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic

14-Oct-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See original here:
Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert

Posted in California Stem Cells | Comments Off on Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue – EurekAlert

Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in…

Posted: October 16, 2021 at 2:29 am

NEW YORK, Oct. 14, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn in progressive multiple sclerosis. The study, "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis," will be delivered in an oral presentation today at the fully digital37thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The Phase 2 clinical trial was designed to evaluate intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS. The study achieved the primary endpoint of safety and tolerability. It demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in the cerebrospinal fluid (CSF) and consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision and cognition.

"We were pleased that this study demonstrated safety, preliminary evidence of efficacy and relevant biomarker outcomes in patients with progressive multiple sclerosis, in an area of high unmet need," said Jeffrey Cohen, M.D., Director of Experimental Therapeutics at the Cleveland Clinic Mellen Center for MS and principal investigator for the trial. "These results should be confirmed in a randomized placebo-controlled trial."

The study was sponsored by Brainstorm Cell Therapeutics with additional financial support for biomarker analyses from the National Multiple Sclerosis Society Fast-Forward Program. It was conducted at four U.S. MS centers of excellence:

"We very much appreciate the tremendous collaboration among many premier organizations, for their generous sharing of expertise, support and data, which enabled the important balance between scientific rigor and ethical treatment of progressive MS participants in the trial," said Ralph Kern, M.D., MHSc., President and Chief Medical Officer, Brainstorm Cell Therapeutics. "We are holding discussions with key MS experts, and seeking guidance from the FDA to determine next steps for the development of NurOwn in progressive MS."

"The National MS Society is pleased to support the biomarker portion of this study through our commercial funding program Fast Forward," said Mark Allegretta, Ph.D., Vice President, Research. "We're encouraged to see evidence that the biomarker analysis showed proof of concept for detecting neuroprotection and reduced inflammation."

About the trial

The Phase 2 open-label studyevaluated the safety and efficacy of intrathecal administration of autologous MSC-NTF cells in patients with primary or secondary progressive MS. The primary study endpoint was safety and tolerability. Secondary efficacy endpoints included: timed 25-foot walk (T25FW); 9-Hole Peg Test (9-HPT); Low Contrast Letter Acuity (LCLA); Symbol Digit Modalities Test (SDMT); 12 item MS Walking Scale (MSWS-12); as well as cerebrospinal fluid (CSF) and blood biomarkers. Clinical efficacy outcomes were compared with matched (n=48) participants in the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) registry, Tanuja Chitnis, MD Brigham and Women's Hospital and the Ann Romney Center for Neurologic Diseases, and 255 patient randomized double blind placebo controlled NN-102 SPRINT-MS Study, courtesy NIH/NINDS, PI: Robert J. Fox, MD, MS, FAAN, Cleveland Clinic, CTR: NCT01982942. Baseline characteristics from these two cohorts were similar allowing for comparison of efficacy results, comparisons with SPRINT-MS were with the placebo arm of this study.

Mean age of participants was 47 years, 56% were female, and mean baseline EDSS score was 5.4. 18 participants were treated, 16 (80%) received all 3 treatments and completed the entire study; 2 study discontinuations were due to procedure-related adverse events. No deaths or treatment-related adverse events due to worsening of MS were observed.

In responder analyses, 14% and 13% of MSC-NTF treated participants showed at least a 25% improvement in T25FW and 9-HPT (combined hands) respectively, compared to 5% and 0% in matched CLIMB patients and 9% and 3% in SPRINT. Twenty-seven percent (27%) showed at least an 8-letter improvement in LCLA (binocular, 2.5% threshold) and 67% showed at least a 3-point improvement in SDMT, compared to 6% and 18% in CLIMB and 13% and 35% in SPRINT, respectively.

Mean improvements of +0.10 ft/sec in T25FW and -0.23 sec in 9-HPT (combined hands), were observed in MSC-NTF treated participants, compared to a mean worsening of -0.07 ft/sec and +0.49 sec in CLIMB and -0.06 ft/sec and +0.28 sec in SPRINT, respectively. MSC-NTF treated participants showed a mean improvement of +3.3 letters in LCLA (binocular, 2.5% threshold) and 3.8 points in SDMT, compared to a mean worsening of -1.07 letters in LCLA (binocular, 2.5% threshold) and mean improvement of +0.10 in SDMT, in CLIMB and -0.6 and -0.1 in SPRINT. In addition the MSFC-4 Composite Z-score of T25W, 9-HPT, SDMT and LCLA showed a 0.18 point improvement in MSC-NTF treated participants, while CLIMB and SPRINT showed decreases of -0.02 and -0.05.

Furthermore, 38% of treated patients showed at least a 10-point improvement in the MSWS-12 a patient reported outcome that evaluates the impact of MS on walking function, whereas this outcome was not evaluated in CLIMB or SPRINT.

CSF biomarkers obtained at 3 consecutive time points, showed increases in neuroprotective molecules (VEGF, HGF, NCAM-1,Follistatin, Fetuin-A) and decreases in neuroinflammatory biomarkers (MCP-1, SDF-1, sCD27 and Osteopontin).

About NurOwn

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwntechnology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).

For more information, visit the company's website atwww.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future NurOwnmanufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwntreatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwntreatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwntreatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Contacts:

Investor Relations:Eric GoldsteinLifeSci Advisors, LLCPhone: +1 (646) 791-9729egoldstein@lifesciadvisors.com

Media:Mariesa Kemble kemblem@mac.com

View original content:

SOURCE Brainstorm Cell Therapeutics Inc

View post:
Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in...

Posted in California Stem Cells | Comments Off on Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in…

Diabetes: Two subtle warning signs signalling the condition has become sight-threatening – Express

Posted: October 16, 2021 at 2:28 am

Diabetes is the result of poor insulin production - a hormone that controls how much sugar circulates in the blood - in the pancreas. Many are able to manage their blood sugar by sticking to a restrictive diet, but those who don't could be putting themselves at risk of vision loss. Giles Edmonds, clinical services director at supersavers, explains that two signs in the eyes warrant immediate medical help.

As retinopathy develops, blood vessels can weaken, bulge or leak into the retina and be referred to as non-proliferative retinopathy, explained Edmonds.

However, if it worsens, some vessels can close off which causes new ones to grow or proliferate, on the surface of the retina.

This is known as proliferative retinopathy and can lead to problems with your vision and even sight loss.

As the blood vessels overgrow or start leaking and the retina becomes impaired, two notable signs may arise.

DONT MISS:

The first signs of this damage could be signalled through floaters, which are spots in your vision that usually resemble black or grey specks.

These cobweb-looking shapes may become particularly apparent when you move your eyes.

Mr Edmonds explained Most people will experience floaters in their vision at some point in their life - particularly as we reach older age as the jelly-like substance in our eyes becomes more liquid.

If you notice more eye floaters than usual, a sudden onset of new ones, flashes of lights in the eye or darkness on any side of your vision, you must get it looked at immediately as in some cases it can be a symptom of diabetic retinopathy."

Blurred vision is another associated with a litany of conditions - and the majority of cases will be benign.

In diabetics, however, damage to the blood vessels in the eyes that sense light can result in vision becoming blurred.

Mr Edmonds added: Blurry vision can also be a symptom of diabetes which can resolve when blood sugars start to reduce after diagnosis and starting treatment.

It can also lead to dimmer vision as if youre wearing sunglasses or struggling to see when its dark, which are important signs not to ignore.

For those who are diabetic, getting dilated eye exams is imperative to protecting the eyes from sight loss.

Certain lifestyle habits, such as eating a healthy diet, could also stave off or delay vision loss.

A line of research has shown that keeping fit through regular exercise could also reduce your chances of getting diabetic retinopathy.

In fact, all the preventative measures recommended for diabetes, also hold promise for retinopathy.

Read more:
Diabetes: Two subtle warning signs signalling the condition has become sight-threatening - Express

Posted in Diabetes | Comments Off on Diabetes: Two subtle warning signs signalling the condition has become sight-threatening – Express

6 Things That Aren’t Helpful to Say to Someone with Type 2 Diabetes – Healthline

Posted: October 16, 2021 at 2:28 am

We arent looking for you to solve our issues or do medical research. We just want your friendship, love, and compassion.

When I was diagnosed with type 2 diabetes, I carefully chose how to share this news. In a world where type 2 is looked at strictly as a lifestyle disease, sharing my diagnosis was not something I was looking forward to.

Once it became common knowledge, well-intentioned family and friends started offering unsolicited advice and sharing anecdotes that werent warmly received. What was supposed to come across as caring and interested came across as condescending and rude.

Now, in the age of social media, well-meaning strangers have joined the discussion.

Type 2 diabetes is a very individual and complicated chronic condition. The world tends to minimize diabetes management by focusing only on weight loss, diet, and exercise.

The reality is, so much more affects our numbers: stress, weather, medications, mental health, illness, sleep, and what color socks were wearing. (OK, that last one is a joke. But in all seriousness, it seems everything can impact our blood sugar levels.)

No matter the intentions behind your advice, please think twice before saying any of the following to a person living with type 2 diabetes.

If someone close to you confides in you about their diagnosis or medication side effects, listen with compassion without thinking about what youre going to say next and without trying to solve anything.

While weight loss can certainly help lower blood glucose in people with diabetes, it is not a cure.

Any sentence that starts with just trivializes the complex nature of glucose control. Just watch what you eat, just count carbs, and just exercise are other statements that fall into this category.

If it were just that easy, the millions of people living with type 2 diabetes would have done it already.

There are so many shakes, supplements, and magic potions specifically targeted to people with diabetes.

Someone once told me if I drank okra water daily, it would cure me. First, yuck, and second, if there was a miracle cure out there, the whole world would be talking about it.

We know that real progress is based on sustainable lifestyle changes. Please dont try to sell us on a quick fix you read about on social media.

First, every persons diabetes is different. So, your grandmothers diabetes is not my diabetes.

Most patients with a type 2 diagnosis are well aware of the complications that may arise as a result of the condition. Some may even use this knowledge as a motivator to eat well, take their medications as advised, and exercise more.

Hearing secondhand stories like this can take that motivation and turn it into fear, causing us to live in a constant state of anxiety. We know the realities that come with this disease and are trying our best to stay positive and control the things we can, like how we eat, how we move, how we think, and how we react to others.

This statement is harmful for so many reasons, and Im not even sure I understand the intent. Is it to make us feel better by comparing our chronic condition to someones cancer battle?

Its never OK to minimize a persons feelings by saying it can always be worse. This goes for pretty much any scenario in life, but medical conditions especially.

Theres a misconception that type 2 diabetes can be cured or reversed using a specific diet or by losing a significant amount of weight. Diabetes remission can be achieved by some, but not everyone is able to completely get off medication, even if they are doing everything right.

Implying that a loved one (or stranger) must not be trying hard enough because they need medication only serves a healthy helping of shame and guilt, emotions they may already feel due to the pressure they put on themselves.

I saved the best and most frustrating for last. Every person I know who is living with diabetes has had this sentence said to them.

Living with type 2 diabetes is a 24/7 job. We are always thinking about food and the way our bodies are going to react to our choices. But that doesnt mean we need policing.

Being a grown woman with type 2 diabetes does not mean I should never enjoy a tasty treat. Its likely if Im eating something indulgent, Ive planned for it, and am excited about it.

The food police comments may be made with genuine concern, but to the person living with type 2, they only serve as a vehicle to shame us for our choices under the guise of being worried about our health.

A type 2 diabetes diagnosis can be difficult to navigate. We want support from our friends and family without unsolicited advice.

When were sharing our frustrations and emotions, we need two things from you: a safe place and open ears.

We arent looking for you to solve our issues or do medical research. We just want your friendship, love, and compassion.

Remember, were given two ears and just one mouth for a reason so we can listen twice as much as we talk.

Mary Van Doorn lives in Georgia with her husband, their two kids, three dogs, and three cats. Shes a type 2 diabetes advocate and the founder of Sugar Mama Strong and Sugar Mama Strong Diabetes Support. When shes not taking care of the kids, the house, or the zoo, you can find her binge-watching her favorite shows: Greys Anatomy, This Is Us, and A Million Little Things.

Originally posted here:
6 Things That Aren't Helpful to Say to Someone with Type 2 Diabetes - Healthline

Posted in Diabetes | Comments Off on 6 Things That Aren’t Helpful to Say to Someone with Type 2 Diabetes – Healthline

Type 2 diabetes and dizziness: Causes and treatment – Medical News Today

Posted: October 16, 2021 at 2:28 am

People with diabetes may experience dizziness, either as a symptom of the condition or as a result of dehydration or certain medications. A doctor can help determine the cause and how to manage or treat it.

Diabetes can cause low or high blood sugar, which can make people feel dizzy or lightheaded. High blood sugar can also lead to dehydration, as the body removes excess glucose from the blood through the urine, taking extra water with it.

Certain medications, including those that lower blood sugar, can also cause dizziness.

In this article, we look at the possible causes of dizziness in type 2 diabetes, other symptoms to be aware of, treatment options, and when to see a doctor.

Low blood sugar, or hypoglycemia, can occur in a person with diabetes. Low blood sugar levels, or low glucose levels, are those that fall below the healthy range.

According to the American Diabetes Association (ADA), low blood sugar levels are usually below 70 milligrams per deciliter (mg/dl), although this may be different for each individual.

Research suggests that 1144% of people with diabetes experience dizziness as a symptom of low blood sugar.

Other signs of low blood sugar can include:

Learn more about the symptoms of low blood sugar here.

High blood sugar, or hyperglycemia, can also cause dizziness. In people with type 2 diabetes, the body may not be able to use insulin effectively enough to control blood sugar, leading to hyperglycemia.

According to research from the United Kingdom, in people using insulin to treat diabetes, about 27% and 22% reported feeling lightheaded or dizzy, respectively, as a result of high blood sugar.

Other symptoms of high blood sugar include:

Learn more about the symptoms of high blood sugar here.

People with diabetes have a higher risk of dehydration due to high blood sugar levels. High blood sugar causes the kidneys to remove excess glucose from the blood through urine.

As the kidneys filter glucose out of the blood, they also remove water. This increased urination means that people with high blood sugar can become dehydrated more easily.

Dehydration can cause dizziness. Other symptoms of dehydration include:

Learn more about the symptoms of dehydration here.

It is important that people seek treatment for dizziness resulting from type 2 diabetes. Severe dizziness may affect everyday tasks and quality of life, and it can lead to falls.

Without treatment, some causes of dizziness may progress to serious complications. In severe cases, uncontrolled blood sugar levels may lead to a loss of consciousness or ketoacidosis, which requires emergency medical care.

Severe dehydration can also lead to life threatening complications without treatment.

By following a treatment plan, people can learn how to control the symptoms of type 2 diabetes, maintain healthy blood sugar levels, and prevent dehydration and dizziness.

Anyone experiencing regular dizziness should contact a doctor. They may wish to consider keeping track of when they feel dizzy to help a doctor identify any patterns.

The doctor may carry out a physical examination and assess any other symptoms. They may check blood sugar levels and review the persons medications to determine the cause of the dizziness.

Treating or managing the underlying causes of dizziness in type 2 diabetes may help resolve dizziness.

Monitoring blood sugar can help people maintain levels within a healthy range. People can use a device called a blood glucose monitor, which measures blood glucose levels in a pinprick of blood from the fingertip.

Learn about glucose blood tests and healthy glucose levels here.

Doctors may recommend that people with low blood sugar follow the 15:15 rule. The ADA explains that a person can take 15 grams (g) of carbohydrates and then check their blood sugar levels 15 minutes afterward. If blood sugar is still low, they should take another 15 g.

People can repeat this until their levels are within a normal range. Examples of carbohydrates that can raise low blood sugar efficiently include:

It is important to avoid using complex carbohydrates to treat low blood sugar in an emergency, as these can slow down the time it takes for the body to absorb glucose. The same applies to carbohydrates with fat, such as chocolate.

Once blood sugar levels have returned to a healthy level, a person can eat a healthy snack to prevent their levels from dropping again.

Carbohydrate levels may vary for each individual, and children will need less than 15 g to treat low blood sugar. People can discuss a specific treatment strategy for low blood sugar with a doctor.

In severe cases of low blood sugar, when the 15:15 approach is insufficient, people may need glucagon. Glucagon is a hormone that the pancreas produces to release stored glucose. A person can speak with their doctor to check whether they require prescription glucagon.

Learn more about how insulin and glucagon regulate blood sugar levels here.

People with high blood sugar may be able to lower their levels through exercise and eating a nutritious, well-balanced diet with smaller portions.

If a persons blood sugar level is higher than 240 mg/dl, it may not be safe for them to exercise because ketones may be present in the urine. Ketones are waste products that the body creates when it uses fats as fuel instead of glucose.

Exercising with ketones in the urine may cause blood sugar levels to increase even further. A buildup of ketones can also lead to a life threatening condition called ketoacidosis.

A doctor can offer advice on a safe treatment plan for lowering blood sugar.

Learn some healthy meal plans for people with diabetes here.

Managing high blood sugar may also help treat dehydration. Drinking plenty of water throughout the day can help the body stay well-hydrated. For more severe cases of dehydration, people may need to replenish their electrolytes.

It is best to avoid sugary drinks or fruit juices, as these could increase blood sugar levels.

Learn about the 20 most hydrating foods here.

If medications are causing dizziness, a doctor may be able to alter the dosage or suggest an alternative. It is important that people do not stop taking any medication without speaking with a doctor.

Type 2 diabetes can cause low or high blood sugar and dehydration, all of which can cause people to feel dizzy or lightheaded. Certain medications, including those for diabetes, may also cause dizziness.

Anyone with type 2 diabetes who experiences frequent or severe dizziness should discuss this symptom with a doctor. Dizziness could be a sign of uncontrolled blood sugar or dehydration, both of which can cause severe complications without treatment.

Depending on the underlying cause, a doctor may suggest changing to an alternative medication or taking steps to manage blood sugar or avoid dehydration.

See the article here:
Type 2 diabetes and dizziness: Causes and treatment - Medical News Today

Posted in Diabetes | Comments Off on Type 2 diabetes and dizziness: Causes and treatment – Medical News Today

Cataracts and diabetes: Relationship, symptoms, treatment – Medical News Today

Posted: October 16, 2021 at 2:28 am

People with diabetes may be twice as likely to develop cataracts as those without diabetes. Cataracts are cloudy areas in the lens of the cornea that blur vision.

Diabetes affects around 9.4% of the population of the United States.

A person with diabetes who develops cataracts may not notice their symptoms at first.

People can try several treatment options to reduce the severity of cataracts. The only treatment that can remove them completely is surgery.

This article explores the link between cataracts and diabetes and how cataract surgery can help improve vision.

Diabetes can cause cataracts for several reasons.

People with diabetes can experience damage to blood vessels in the eyes from high blood sugar and swelling in the liquid between the eyeball and cornea lens.

In people with diabetes, the body produces less insulin than it needs or cannot use insulin properly. Insulin moves sugar, or glucose, from the blood into the cells, where the body uses it as energy.

Without sufficient insulin, glucose cannot enter the cells. It then builds up in the bloodstream, resulting in high blood sugar.

When a person has high blood sugar over a long period, it can damage their blood vessels, including those in the eye. This can increase the likelihood of getting a cataract.

Another factor involved in cataracts involves the aqueous humor, which is the liquid that fills the space between the eyeball and the cornea lens.

When glucose levels are high in the aqueous humor, the lens can swell, contributing to blurred vision. A 2021 study on 37 people with diabetes and cataracts found high glucose levels in the aqueous humor. People who had the most difficulty controlling blood sugar had the highest glucose levels in the aqueous humor.

When blood sugar is high for long periods, enzymes in the lens of the cornea convert glucose to sorbitol, which can swell the lens and contribute to blurred vision.

Learn more about the link between diabetes and blurry vision here.

Cataracts form very slowly. A person can have an early-stage cataract without showing any symptoms.

The main signs and symptoms of a cataract include:

Most people with diabetes should see a doctor for a dilated eye exam once a year. A person might need more regular checkups depending on the type of diabetes in question and how long they have had it.

During an eye exam, a doctor will place drops in the persons eyes to widen their pupils. Using a magnifying lens, the doctor will examine the large area at the back of the eye. They will also test the persons vision and the pressure in their eyes. People usually have blurry vision for a few hours after a dilated exam.

If a person notices sudden vision changes, including flashes of light, floaters, or obscured vision, they should call a doctor right away.

There is no way to prevent cataracts from forming, but people with diabetes may lower their risk of developing cataracts by controlling their blood sugar.

Preventative steps include:

Surgery is the only treatment for cataracts. However, for less severe cataracts, it might help a person to:

People with less severe cataracts should monitor changes in their vision and follow a regular eye exam schedule.

When cataracts get in the way of doing daily tasks, a doctor will usually recommend surgery.

Cataract surgery is a relatively safe procedure done under local anesthetic. It can take around 1 hour, although some operations may take less time. People can usually go home the same day.

During surgery, a doctor removes the clouded lens and replaces it with a clear, artificial one. The artificial lens, or intraocular lens, requires no care and can significantly restore the eyes ability to focus. Once a doctor has removed the cataract, it will not grow back.

A doctor can perform two types of surgery to remove a cataract.

The doctor makes a small incision in the side of the cornea and inserts a tiny probe, the same thickness as a human hair. This probe emits ultrasound waves that break up the lens so the doctor can suction it out.

The doctor makes a slightly larger incision in the cornea to remove the lens core in one piece. They then put the artificial lens in place.

Learn more about what to expect during cataract surgery here.

Following cataract surgery, it can take a few days for a persons vision to return fully. They will probably have to wear an eye patch for a day or two after surgery. They may also have to use eye drops to reduce inflammation and the chance of infection.

The presence of other eye diseases such as glaucoma or diabetic retinopathy might affect a persons chances of recovering full vision following surgery.

After surgery, a person may experience temporary, typical symptoms, such as:

After 46 weeks, these side effects should have disappeared.

According to the National Eye Institute, 90% of people can see better after having cataract surgery.

High blood sugar in people with diabetes makes cataracts more likely to form. Older people, those who have difficulty with glycemic control, and people who have had diabetes for a long time are more likely to develop cataracts.

Surgery to replace a cloudy cataract lens with an artificial lens is simple, has a great success rate, and dramatically improves vision for most people.

More here:
Cataracts and diabetes: Relationship, symptoms, treatment - Medical News Today

Posted in Diabetes | Comments Off on Cataracts and diabetes: Relationship, symptoms, treatment – Medical News Today

Diabetes Not Associated with Increased Risk of Long-Term COVID-19 Symptoms – Endocrinology Network

Posted: October 16, 2021 at 2:28 am

A new report from a team of investigators based in Spain is providing evidence that suggests presence of diabetes does not increase risk of long-term post-COVID-19 symptoms.

An analysis of 1800 hospitalized patients from the first wave of the pandemic, results of the study indicate the number of post-COVID symptoms was similar between those with diabetes and those without. Results also indicate there were no between-groups differences observed for any specific post-COVID symptoms.

Current and previous evidence suggest that diabetes seems to play a more relevant role during the acute phase of COVID-19 rather than for the development of post-COVID symptomatology in previously hospitalized COVID-19 survivors, wrote investigators.

Few patient groups have received the amount of attention patients with diabetes have throughout the ongoing COVID-19 pandemic. A common comorbidity among patients with obesity, diabetes quickly became recognized as a risk factor for increased disease severity in patients with COVID-19. As the pandemic has raged on, concern over the long-term effects of COVID-19 has begun to grow. Sometimes referred to as long COVID, ability to predict those at greatest risk of long-term COVID-19 symptoms could have a substantial impact moving forward.

With this in mind, investigators from Spain sought to fill the apparent knowledge gap related to risk of long-term COVID-19 symptoms based on a diagnosis of diabetes by conducting a multicenter case-control study of patients hospitalized for SARS-CoV-2 infection from March 1-May 31, 2020, at a trio of public hospitals in Madrid.

From a sample cohort of 1800 patients hospitalized during the aforementioned time period, investigators identified 145 patients with a diagnosis of diabetes. Using these patients, investigators identified 290 age- and sex-matched controls without diabetes for inclusion. Investigators noted there were no differences in symptoms at hospital admission except for an increased prevalence of myalgia and a greater proportion of patients with diabetes reported comorbid hypertension, obesity, and migraine compared to their counterparts without diabetes.

Patients with diabetes were assessed for symptoms a mean of 7.6 months following hospital discharge. In total, just 19% were completely free of any post-COVID symptom during the follow-up period. Results of the investigators' analyses indicated the number of post-COVID symptoms were similar among patients with diabetes and those without diabetes (IRR, 1.06 [95% CI, 0.92-1.24]; P=.372).

Investigators also noted no differences were observed for presence of fatigue OR, 1.45 [95% ACI, 0.93-2.25]; P=.101), dyspnea on exertion (OR, 0.97 [95% CI, 0.64-1.47]; P=.886), and musculoskeletal pain (OR, 0.951 [95% CI, 0.76-1.18]; P=.367). Investigators also pointed out there were no between-groups differences observed among patients (OR, 1.07[95% CI, 0.71-1.62]; P=.728).

Our study showed that diabetes was not a risk factor for post-COVID symptoms when assessed an average of 7 months post discharge. Further, diabetes was not associated with differences in limitations of daily living activities after hospital discharge, wrote investigators.

This study, Diabetes and the Risk of Long-Term Post-COVID Symptoms, was published in Diabetes.

View post:
Diabetes Not Associated with Increased Risk of Long-Term COVID-19 Symptoms - Endocrinology Network

Posted in Diabetes | Comments Off on Diabetes Not Associated with Increased Risk of Long-Term COVID-19 Symptoms – Endocrinology Network

HIMSSCast: Taking the CDC’s Diabetes Prevention Program digital – Mobihealth News

Posted: October 16, 2021 at 2:28 am

The CDC's Diabetes Prevention Program is one of the first lifestyle- and behavior-based interventions to be proven, in a large clinical study, to be more effective than a comparable drug (in this case metformin). Digital implementations can make the DPP more accessible and more scalable, and a number of digital health companies have been tackling this for the last few years.

Fruit Street Health is one of those companies, and its CEO, Laurence Girard, joins host Jonah Comstock on today's HIMSSCast to discuss the challenges, opportunitiesand successes his company has had in this space.

Like what you hear? Subscribe to the podcast onApple Podcasts,SpotifyorGoogle Play!

Talking points:

More about this episode:

Fruit Street to deliver CDC's National Diabetes Prevention Program through live video classes

Fruit Street Health raises $3 million in doctors-only round

UK passes on Apple, Google's Bluetooth contact tracing tool, Fruit Street Health launches COVID-19 telemedicine platform and more digital health news briefs

AHIP, CDC to partner on diabetes prevention

Medicare to reimburse for Diabetes Prevention Program, including Omada's digital version

Diabetes Prevention Program under the Affordable Care Act is working, HHS Secretary Burwell says

American Medical Association pushes public, private health plans to cover National Diabetes Prevention Program

CMS calls for extending Diabetes Prevention Program into Medicare, proposes new doc fees to boost chronic care

Here is the original post:
HIMSSCast: Taking the CDC's Diabetes Prevention Program digital - Mobihealth News

Posted in Diabetes | Comments Off on HIMSSCast: Taking the CDC’s Diabetes Prevention Program digital – Mobihealth News

Page 631«..1020..630631632633..640650..»